Abbott Laboratories has completed its acquisition of Kos Pharmaceuticals Inc., which specializes in treatments for cardiovascular, metabolic and respiratory diseases, and is now a wholly owned subsidiary of Abbott Labs.

Abbott reports that the acquisition broadens its portfolio of products for lipid management—the world’s largest pharmaceutical segment—and increases its near- and mid-term research and development investment in lipid management, diabetes care and asthma.

“We can now serve patients and doctors better, because we can offer them a broad range of therapies for cholesterol and lipid management,” says Miles D. White, Abbott’s chairman and CEO. “We very much admire the business that Kos built and grew over the past several years. It’s an excellent strategic fit for Abbott, and we’re enthusiastic about the commercial and R&D opportunities our combined organization now offers.”

For more information, visit www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0401.htm.

 …